Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin

Journal of Immunology

Volumn 165, Issue 2, 2000, Pages 869-877

  Van Hall, Thorbald ^a   Van Bergen, Jeroen ^a   Van Veelen, Peter A ^a   Kraakman, Margriet ^a   Heukamp, Lukas C ^a   Koning, Frits ^a   Melief, Cornelis J M ^a   Ossendorp, Ferry ^a   Offringa, Rienk ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PEPTIDE HORMONE; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CARCINOGENESIS; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; T CELL LYMPHOMA; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0034662262     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.2.869     Document Type: Article

References (43)

1. Melief, C. J. M., R. Offringa, R. E. M. Toes, and W. M. Kast. 1996. Peptide-based cancer vaccines. Curr. Opin. Immunol. 8:651.
2. Jaffe, E. M., and D. M. Pardoll. 1996. Murine tumor antigens is it worth the search? Curr. Opin. Immunol. 8:622.
3. Van Pel, A., P. van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethé, B. van den Eynde, C. Uyttenhove, J.-C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes, Immunol. Rev. 145:229.
4. Toes, R. E. M., R. Offringa, M. C. W. Feltkamp, M. J. W. Visseren, S. P. Schoenberger, C. J. M. Melief, and W. M. Kast. 1994. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst. Mitt. 94:72.
5. Boon, T. 1992. Towards a genetic analysis of tumor rejection antigens. Adv. Cancer Res. 58:179.
6. Van den Eynde, B., B. Lethé, A. van Pel, E. de Plaen, and T. Boon. 1991. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene for syngeneic DBA/2 mice. J. Exp. Med. 173:1373.
7. Boon, T., and P. Van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
8. + T cell-stimulating peptide presented by a major histocompatibility complex class I molecule in a murine thymoma. Proc. Natl. Acad. Sci. USA 93:13991.
9. Huang, A. Y. C., P. H. Gulden, A. S. Woods, M. C. Thomas, C. D. Tong, W. Wang, V. H. Engelhard, G. Pasternack, R. Cotter, D. Hunt, et al. 1996. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad Sci. USA 93:9730.
10. Feenstra, A., J. Fewell, K. Luenders, and E. Kuff. 1986. In vitro methylation inhibits the promoter activity of a cloned intracistemal A-particle LTR. Nucleic Acids Res. 14:4343.
11. Florl, A. R., R. Lower, B. J. Schmitz-Drager, and W. A. Schultz. 1999. DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br. J. Cancer 80:1312.
12. Castelli, C., L. Rivoltini, G. Andreola, M. Carrabba, N. Renkvist, and G. Parmiani. 2000. T-cell recognition of melanoma-associated antigens. J. Cell. Physiol. 182:323.
13. Bloom, M. B., D. Perry-Lalley, P. F. Robbins, Y. Li, M. El-Gamil, A. Rosenberg, and J. C. Yang. 1997. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J. Exp. Med. 185:453.
14. Ossendorp, F., E. Mengedé. M. Camps, R. Filius, and C. J. M. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693.
15. b mutant bm 13 mice. J. Virol. 68:6038.
16. Chen, W., H. Qin, B. Chesebro, and M. A. Cheever. 1996. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney and Rauscher murine leukemia virus-induced tumors. J. Virol. 70:7773.
17. Iwashiro, M., T. Kondo, T. Shimizu, H. Yamagishi, K. Takahashi, Y. Matsubayashi, T. Masuda, A. Otaka, N. Fuiji, A. Ishimoto, et al. 1993. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J. Virol. 67:4513.
18. Flyer, D. C., S. J. Burakoff, and D. V. Faller. 1986. The immune response to Moloney murine leukemia virus-induced tumors: induction of cytolytic T lymphocytes specific for both viral and tumor-associated antigens. J. Immunol. 137: 3968.
19. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiesling. 1986. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675.
20. McCoy, J. L., A. Fefer, and J. P. Glynn. 1967. Comparative studies on the induction of transplantation resistance in BALB/c and C57BL/6 mice in three leukemia systems. Cancer Res. 27:1743.
21. Klein, E., and G. Klein. 1964. Antigenic properties of lymphomas induced by the Moloney agent. J. Natl. Cancer Inst. 32:547.
22. Kast, W. M., R. Offringa, P. J. Peters, A. C. Voordouw, R. H. Meloen, A. J. Van der Eb, and C. J. M. Melief. 1989. Eradication of adenovirus E1-induced tumors by Ela-specific cytotoxic T lymphocytes. Cell 59:603.
23. Sijts, E. J. A. M., F. Ossendorp, E. A. M. Mengedé, P. J. Van den Elsen, and C. J. M. Melief. 1994. An immunodominant MCF murine leukemia virus encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV type specificity of MCF-directed CTL. J. Immunol. 152:106.
24. b mutants. J. Immunol. 128:1360.
25. Van Hall, T., N. E. Van de Rhee, S. P. Schoenberger, M. P. M. Vierboom, F. A. W. Verreck, C. J. M. Melief, and R. Offringa. 1998. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res. 58:3087.
26. Stukart, M. J., A. Vos, and C. J. M. Melief. 1981. Cytotoxic T-cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus: methodological aspects and H-2 requirements. Eur. J. Immunol. 11:251.
27. Feltkamp, M. C. W., M. P. M. Vierboom, W. M. Kast, and C. J. M. Melief. 1994. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol. Immunol. 31:1391.
28. Casanova, J.-L., P. Romero, C. Widmann, P. Kourilsky, and J. L. Maryanski. 1991. T cell receptor genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte clones specific for a Plasmodium berghei nonapeptide: implications for T cell allelic exclusion and antigen-specific repertoire. J. Exp. Med. 174:1371.
29. Den Haan, J. M. M., N. E. Sherman, E. Blokland, E. Huczko, F. Koning, J. W. Drijfhout, J. Skipper, J. Shabanowitz, D. F. Hunt, V. H. Engelhard, et al. 1995. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 268:1476.
30. Arnott, D., J. Shabonawitz, and D. F. Hunt. 1993. Mass spectrometry of proteins and peptides: sensitive and accurate mass measurement and sequence analysis. Clin. Chem. 39:2005.
31. + cytolytic clones which recognize a tumor-specific cell surface antigen. J. Immunol. 135:703.
32. Franksson, L., M. Petersson, R. Kiessling, and K. Karre. 1993. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur. J. Immunol. 23:2606.
33. Rammensee, H.-G., K. Falk, and O. Rötschke. 1993. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:213.
34. Nelson-Rees, W. A., and R. R. Flandermeyer. 1976. HeLa cultures defined. Science 191:96.
35. MacLeod, R. A. F., W. G. Dirks, Y. Matsuo, M. Kaufmann, H. Milch, and H. G. Drexler. 1999. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int. J. Cancer 83:555.
36. Drexler, H. G., W. G. Dirks, and R. A. F. MacLeod. 1999. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601.
37. Nelson-Rees, W. A., D. W. Daniels, and R. R. Flandermeyer. 1981. Cross-contamination of cells in culture. Science 212:446.
38. Ikeda, H., N. Ohta, K. Furukawa, H. Miyazaki, L. Wang, K. Kuribayashi, L. J. Old, and H. Shiku. 1997. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc. Natl. Acad. Sci. USA 94:6375.
39. Bilsborough, J., A. Van Pel, C. Uyttenhove, T. Boon, and B. J. Van den Eynde. 1999. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J. Immunol. 162:3534.
40. Kwong, Y. Y., Z. Husain, and D. K. Biswas. 1992. c-Ha-ras gene mutation and activation precede pathological changes in DMBA-induced in vivo carcinogenesis. Oncogene 7:1481.
41. Von Pressentin, M. M., W. Kosinkska, and J. B. Guttenplan. 1999. Mutagenesis induced by oral carcinogens in lacZ mouse (MutaMouse) tongue and other oral tissues. Carcinogenesis 20:2167.
42. Vierboom, M. P. M., H. W. Nijman, R. Offringa, E. I. H. van der Voort, T. van Hall, L. van den Broek, G. J. Fleuren, P. Kenemans, W. M. Kast, and C. J. M. Melief. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186:695.
43. Gays, F., M. Unnikrishnan, S. Shrestha, K. P. Fraser, A. R. Brown, C. M. Tristram, Z. M. Chrzanowska-Lightowlers, and C. G. Brooks. 2000. The mouse tumor cell lines EL4 and RMA display mosaic expression of NK-related and certain other surface molecules and appear to have a common origin. J. Immunol. 164:5094-5102.